Application for Block Listing

RNS Number : 2633P
Futura Medical PLC
25 May 2018
 

 

25 May 2018

 

 

 

Futura Medical plc

("Futura" or "the Company")

 

Application for Block Listing 

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology today announces that an application has been made to the London Stock Exchange to extend its block listings of securities by a total of 1,190,000 ordinary shares of 0.2 pence each (the "New Ordinary Shares") which may arise pursuant to the exercise of options under the Company's Unapproved Share Option Scheme and its EMI Share Option Scheme.

It is expected that admission will become effective on or around 30 May 2018 ("Admission"). Following Admission, the Company will notify its Schedule Six (block listing interim review) update for the period from 25 November 2017 to 30 May 2018.

Any New Ordinary Shares issued will be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares of the Company.

 

For further information please contact:

 

Futura Medical plc

 

James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

Email to: james.barder@futuramedical.com

www.futuramedical.com

 

N+1 Singer (Nominated Adviser and Broker)

 

Aubrey Powell / Liz Yong

Corporate Finance

 

Tel:+44 (0) 20 7496 3000

For media enquiries please contact:

 

Buchanan

 

Mark Court / Sophie Cowles / Stephanie Watson

Tel: +44 (0) 20 7466 5000

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ALSFMGZKNDVGRZM
UK 100

Latest directors dealings